Psoriatic arthritis is a chronic inflammatory arthritis associated with psoriasis, causing joint pain, stiffness, swelling, and possible progressive joint damage if untreated.
Johnson & Johnson said Tremfya met the primary endpoint in the Phase 3 FUZION study in active perianal fistulizing Crohn’s disease. At Week 24, both Tremfya dosing regimens showed statistically significant combined fistula remission versus placebo.
Dr. Reddy's said the FDA accepted for review its 351(k) BLA for DRL_AB, a proposed interchangeable biosimilar to ORENCIA. The application covers an IV formulation for RA, PsA and pJIA.
Bio-Thera Solutions expands its partnership with Intas Pharmaceuticals for BAT2506, a golimumab biosimilar, through an exclusive commercialization agreement for India. The India biosimilars market is projected to grow from $184 million to $1.02 billion by 2035, driven by patent expirations and strategic partnerships.
AbbVie reported Q4 earnings that beat consensus estimates with $16.62 billion in revenue, while facing competitive setbacks in psoriatic arthritis and Medicare pricing challenges for Botox.
The FDA is expected to issue draft guidance reducing testing requirements for biosimilar drugs, potentially lowering development costs by USD 20 million. The move comes as the biosimilars market shows strong growth, with major launches in 2025.
The FDA has accepted for review Beren Therapeutics' NDA for adrabetadex in infantile-onset Niemann-Pick disease type C with a PDUFA date of August 17, 2026, and Dr. Reddy's BLA for a biosimilar to Orencia (abatacept).
The US FDA has accepted Dr Reddy's Biologics License Application for DRL-AB, a proposed interchangeable biosimilar to Orencia (abatacept) for intravenous infusion, marking the first abatacept biosimilar submission.
The FDA has accepted Dr. Reddy's Laboratories' BLA for DRL_AB, a proposed interchangeable biosimilar to abatacept, submitted in December 2025. The application is the first for an abatacept biosimilar and is supported by Phase 1 data showing pharmacokinetic similarity.
Dr. Reddy's Laboratories has received FDA acceptance for its biosimilar application targeting Bristol-Myers Squibb's Orencia, marking the first U.S. application for an off-patent version of the arthritis treatment that generated $2.7 billion in 2025.
Phase 3b TOGETHER-PsO trial shows concomitant use of ixekizumab and tirzepatide delivered superior skin clearance and weight loss versus monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594054 |
Inflammation Digital Biomarkers Validation Study |
NOT_YET_RECRUITING | |
| NCT07580092 |
Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With Inflammatory Joint Disease |
COMPLETED | |
| NCT07567378 |
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry |
NOT_YET_RECRUITING | |
| NCT07486960 |
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) |
RECRUITING | PHASE2 |
| NCT07406035 |
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07403890 |
Rewiring the Brain-Immune Axis for Chronic Pain Using Transcranial Magnetic Stimulation in Psoriatic Arthritis |
NOT_YET_RECRUITING | NA |
| NCT07398651 |
Apremilast and Adalimumab in Psoriatic Arthritis Patients |
NOT_YET_RECRUITING | NA |
| NCT07386717 |
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis |
COMPLETED | |
| NCT07352696 |
Combined High-Intensity Aerobic Training and Resistance Training in Psoriatic Arthritis |
NOT_YET_RECRUITING | NA |
| NCT07329556 |
Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases |
NOT_YET_RECRUITING |
